6-Hydroxydopa (6-OH-DOPA; 6-OHDOPA) is a catecholaminergic neurotoxin that damages noradrenergic and dopaminergic neurons and is used in scientific research.[1][2][3] It is a precursor and prodrug of 6-hydroxydopamine (6-OHDA).[1][2][3] The drug is a derivative of levodopa (L-DOPA).[1][2][3] It has certain advantages over 6-OHDA, such as the ability to cross the blood–brain barrier into the central nervous system and hence the ability to be administered systemically rather than directly into the brain.[1][2][3] 6-OH-DOPA was first described in the scientific literature by 1969.[4]
References
- ^ a b c d Kostrzewa RM (2022). "Survey of Selective Monoaminergic Neurotoxins Targeting Dopaminergic, Noradrenergic, and Serotoninergic Neurons". Handbook of Neurotoxicity. Cham: Springer International Publishing. pp. 159–198. doi:10.1007/978-3-031-15080-7_53. ISBN 978-3-031-15079-1.
- ^ a b c d Kostrzewa RM (2016). "Perinatal Lesioning and Lifelong Effects of the Noradrenergic Neurotoxin 6-Hydroxydopa". Current Topics in Behavioral Neurosciences. Vol. 29. pp. 43–50. doi:10.1007/7854_2015_414. ISBN 978-3-319-34134-7. PMID 26660536.
- ^ a b c d Kostrzewa RM, Brus R (1998). "Destruction of catecholamine-containing neurons by 6-hydroxydopa, an endogenous amine oxidase cofactor". Amino Acids. 14 (1–3): 175–179. doi:10.1007/BF01345259. PMID 9871458.
- ^ Ong HH, Creveling CR, Daly JW (May 1969). "The synthesis of 2,4,5-trihydroxyphenylalanine (6-hydroxydopa). A centrally active norepinephrine-depleting agent". Journal of Medicinal Chemistry. 12 (3): 458–462. doi:10.1021/jm00303a028. PMID 5788162.